Thorac Cardiovasc Surg 2008; 56(1): 56-57
DOI: 10.1055/s-2007-965765
Short Communication

© Georg Thieme Verlag KG Stuttgart · New York

Mitral Valve Replacement and Tricuspid Valve Repair in a Patient with Sickle Cell Disease

G. Lazopoulos1 , M. M. Kantartzis2 , M. Kantartzis1
  • 1Department of Cardiac Surgery, Athens Medical Center, Athens, Greece
  • 2Department of Anesthesiology, Athens Medical Center, Athens, Greece
Further Information

Publication History

Received April 12, 2007

Publication Date:
17 January 2008 (online)

Preview

Introduction

Sickle cell disease (SCD) was first described by a Chicago physician, Herrik, in 1910. The sickle cell gene (S gene) has a worldwide distribution but has its greatest concentration in West Central Africa, the northeast corner of Saudi Arabia and East Central India. Homozygous sickle cell disease produces a chronic incurable illness with unpredictable life-threatening events. However, the sickle cell trait (SCT), the carrier state, is almost completely benign.

A reduction of the hemoglobin S (HbS) fraction to less than 30 % is required for patients undergoing cardiopulmonary bypass (CPB) [[1]]. This can be achieved by simple transfusion, partial exchange transfusion, complete exchange transfusion with the cardiopulmonary bypass circuit, or a combination of these techniques [[2], [3]].

We report the management of a Greek woman, with homozygous SCD and rheumatoid arthritis, who underwent partial exchange transfusion preoperatively and subsequent mitral valve replacement and tricuspid valve repair at normothermia.

References

Dr. MD, PhD George Lazopoulos

Department of Cardiac Surgery
Athens Medical Center

Distomou 5 - 7 str.

15125 Athens

Greece

Fax: + 30 21 06 12 57 51

Email: lazopoulosg@ath.forthnet.gr